Tradestie Institutional Equity Comparison Engine · Market Close Jan 30, 2026

MNMD vs MPW: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MPW Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 7–3 Matrix Metrics)

MPW Overall Winner 6-Pillar Tally: MNMD 0 – 6 MPW Matrix Metrics: MNMD 3 – 7 MPW

As of Jan 30, 2026, Medical Properties Trust, Inc. (MPW) is the stronger overall head-to-head candidate over Mind Medicine (MindMed) Inc. Common Shares (MNMD) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MNMD carries a Unified Composite Score of 63.1/100 (BUY) at $15.02 (N/M Forward P/E, 0.0% operating margin), whereas MPW carries 52.6/100 (HOLD) at $5.02 (6.7x Forward P/E, 58.2% operating margin).

  • Composite vs. Pillar Nuance: While MNMD currently prints a higher short-term Unified Composite Score (63.1/100 BUY vs. MPW 52.6/100 HOLD), MPW captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (58.2% vs. 0.0% operating margin) and revenue trajectory (+9.9% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MNMD vs MPW
MNMD NASDAQ
Mind Medicine (MindMed) Inc. Common Shares
Medicinal Chemicals & Botanical Products
$15.02
+1.01% 1D
Market Cap $1.4B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.79β · 55% Vol
Unified Composite Score
63.1 / 100 BUY
Tech 75.0 Fund 62.0 Flow 60.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.7% over 20 days), RSI 65
RSI-14: 65.3 · SMA20: $13.52 · SMA50: $12.57
MPW NYSE Head-to-Head Winner
Medical Properties Trust, Inc.
Real Estate Investment Trusts
$5.02
-0.59% 1D
Market Cap $3.0B
TTM Revenue $1.01B
Forward P/E 6.7x
Beta / 30D Vol 0.14β · 26% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 25.0 Fund 45.0 Flow 67.0 Mom 47.3
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.4 · SMA20: $5.18 · SMA50: $5.24

6-Pillar Scorecard Institutional Category Breakdown (MNMD 0 – 6 MPW)

Columns: Metric · MNMD · MPW
1. Valuation Multiples MPW
Forward P/E N/M 6.7x
Trailing P/E N/M 6.7x
PEG Ratio N/M 1.93x
EV / Revenue N/M 3.0x
2. Growth & Scale MPW
Revenue Growth (YoY) +0.0% +9.9%
Earnings Growth (YoY) +0.0% -48.6%
TTM Revenue (USD) N/A $1.01B
Market Cap $1.4B $3.0B
3. Profitability & Quality MPW
Gross Margin N/A 96.4%
Operating Margin 0.0% 58.2%
Net Profit Margin 0.0% -70.1%
Return on Equity (ROE) -85.6% -14.0%
4. Balance Sheet & Cash Flow MPW
Cash Generation (TTM) N/A $823M EBITDA
Cash Flow Margin N/A 81.6% EBITDA Mgn
Net Cash / Leverage $1.70 Book/Sh · -85.6% ROE $7.75 Book/Sh · -14.0% ROE
Dividend Yield None (0.00%) 6.34%
5. Options & Positioning MPW
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 70.7% (6th %ile) 24.3% (25th %ile)
Put/Call OI Skew 0.18x (Call-Skewed) 0.79x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat MPW
OpEx & R&D Intensity N/A 38.2% of Rev ($385M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator REIT - Healthcare Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MNMD (3) vs MPW (7)
Institutional Metric MNMD MPW Criterion Row Edge
Market Capitalization
Scale
$1.4B $3.0B Larger Scale MPW
Trailing P/E Ratio
Valuation
N/M 6.7x Lower Multiple MPW
Forward P/E Ratio
Valuation
N/M 6.7x Lower Multiple MPW
Revenue Growth (YoY)
Growth
+0.0% +9.9% Higher Growth MPW
Operating Margin (TTM)
Profitability
0.0% 58.2% Higher Margin MPW
Net Profit Margin
Profitability
0.0% -70.1% Higher Margin MNMD
Return on Equity (ROE)
Capital Efficiency
-85.6% -14.0% Higher ROE MPW
52-Week Range Position
Momentum
98% ($5–$15) 45% ($4–$6) Stronger Trend MNMD
Beta / 30D Volatility
Risk Regime
1.79β · 55% Vol 0.14β · 26% Vol Lower Realized Risk MPW
Unified Institutional Score
Composite Signal
63.1 / 100 (BUY) 52.6 / 100 (HOLD) Higher Composite MNMD
Trailing 12M Revenue (USD)
Operating Scale
N/A $1.01B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 96.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.93x PEG · 3.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($1.70 Book/Sh · -85.6% ROE) $823M EBITDA ($7.75 Book/Sh · -14.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MNMD +18.95 pp
MNMD: +19.54% · MPW: +0.59%
3M Horizon MNMD +20.55 pp
MNMD: +19.02% · MPW: -1.53%
6M Horizon MNMD +49.69 pp
MNMD: +75.06% · MPW: +25.37%
1Y Horizon MNMD +88.37 pp
MNMD: +105.19% · MPW: +16.82%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MNMD vs MPW. Trailing 12-month operating profitability (MNMD 0.0% vs MPW 58.2%) and valuation multiples (MNMD N/M vs MPW 6.7x Forward P/E) are benchmarked directly in Pillar 4 below.

MNMD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-85.6% · N/M
MPW ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.01B
Gross Margin96.4%
Op. Margin58.2%
ROE / Fwd P/E-14.0% · 6.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MNMD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 70.7%
IV Percentile 6th %ile
Put/Call OI Skew 0.18x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MNMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MPW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 24.3%
IV Percentile 25th %ile
Put/Call OI Skew 0.79x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MPW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MNMD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MPW Moat Profile High-Margin Pricing Power Moat
REIT - Healthcare Facilities Operator
Competes within the REIT - Healthcare Facilities value chain with $3.0B market capitalization and 58.2% operating margin.
OpEx & R&D Reinvestment 38.2% of Rev ($385M)
90D Engineering Disclosures 0 Published

Investor FAQ MNMD vs MPW Key Questions & Quantitative Answers

As of Jan 30, 2026, Medical Properties Trust, Inc. (MPW) is the stronger overall head-to-head candidate over Mind Medicine (MindMed) Inc. Common Shares (MNMD) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MNMD carries a Unified Composite Score of 63.1/100 (BUY) at $15.02 (N/M Forward P/E, 0.0% operating margin), whereas MPW carries 52.6/100 (HOLD) at $5.02 (6.7x Forward P/E, 58.2% operating margin). Composite vs. Pillar Nuance: While MNMD currently prints a higher short-term Unified Composite Score (63.1/100 BUY vs. MPW 52.6/100 HOLD), MPW captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (58.2% vs. 0.0% operating margin) and revenue trajectory (+9.9% vs. +0.0% YoY).

MPW leads the Growth & Scale pillar: MNMD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MPW at +9.9% YoY revenue growth and -48.6% YoY earnings growth on $1.01B TTM revenue (96.4% gross margin, 58.2% operating margin). On trailing 12-month operating scale, MNMD generates N/A in USD-normalized revenue versus $1.01B for MPW. In operating R&D and SG&A reinvestment, MNMD deploys N/A (0 90-day corporate R&D disclosures) versus 38.2% of Rev ($385M) (0 disclosures) for MPW.

MPW screens cheaper on headline valuation multiples. MNMD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas MPW trades at 6.7x Forward P/E, 6.7x Trailing P/E, 1.93x PEG, and 3.0x EV/Revenue (81.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MNMD (-85.6% ROE) versus MPW (-14.0% ROE) capital efficiency.

In options market volatility and institutional positioning, MNMD carries 70.7% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.18x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.79β · 55% Vol realized risk). By comparison, MPW carries 24.3% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.79x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 26% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Jan 30, 2026. For educational research only; not investment advice.